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and promotes strategic cognitive 
performance in a rodent 
touchscreen task
Lena‑Sophie Martis1,2, Kristoffer Højgaard1,3, Megan C. Holmes2,4, Betina Elfving1 & 
Ove Wiborg5*
Depression‑associated cognitive impairments are among the most prevalent and persistent symptoms 
during remission from a depressive episode and a major risk factor for relapse. Consequently, 
development of antidepressant drugs, which also alleviate cognitive impairments, is vital. One such 
potential antidepressant is vortioxetine that has been postulated to exhibit both antidepressant 
and pro‑cognitive effects. Hence, we tested vortioxetine for combined antidepressant and pro‑
cognitive effects in male Long‑Evans rats exposed to the chronic mild stress (CMS) paradigm. This 
well‑established CMS paradigm evokes cognitive deficits in addition to anhedonia, a core symptom 
of depression. Learning and memory performance was assessed in the translational touchscreen 
version of the paired‑associates learning task. To identify the mechanistic underpinning of the 
neurobehavioural results, transcriptional profiling of genes involved in the stress response, neuronal 
plasticity and genes of broad relevance in neuropsychiatric pathologies were assessed. Vortioxetine 
substantially relieved the anhedonic‑like state in the CMS rats and promoted acquisition of the 
cognitive test independent of hedonic phenotype, potentially due to an altered cognitive strategy. 
Minor alterations in gene expression profiling in prefrontal cortex and hippocampus were found. 
In summary, our findings suggest that vortioxetine exhibits an antidepressant effect as well as 
behavioural changes in a translational learning task.
Worldwide, around 264 million people suffer from major depressive disorder (MDD) making this the leading 
burden of disability  worldwide1. The recurrent nature of the disease together with insufficient responses to anti-
depressant treatment add to the devastating burden of the  disease2. Core symptoms of MDD are a depressed 
mood and an attenuated anticipation or experience of pleasure (anhedonia). Additionally, patients suffer from a 
variable number of associated symptoms, such as impaired cognitive abilities, which affect primarily attention, 
executive functions and memory. These cognitive symptoms persist in 30–60% of treated patients after remis-
sion from the affective MDD symptoms. Furthermore, cognitive impairments are the most persisting residual 
symptoms of depression and, hence, continue to decrease daily functioning and quality of life after  remission3–6. 
Moreover, persistent cognitive impairments augment risk of relapse and are increasingly regarded as a core 
component rather than an epiphenomenon of  depression7,8. Recovery from cognitive symptoms is associated 
with a rapid remission from  depression9, further underlining the importance of restoring cognitive impairments 
when treating depression.
However, current antidepressant treatment focuses mainly on alleviating the affective symptoms, neglecting 
cognitive  impairments10. Therefore, development of novel, pro-cognitive antidepressants is vital and, hence, a 
translational drug screening platform for depression-associated cognitive impairments is essential. In a previous 
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 study11, it was demonstrated that the chronic mild stress (CMS) paradigm fulfils exactly these criteria. The CMS 
model exhibits the MDD core symptom anhedonia (face validity) evoked by stress exposure (etiological validity). 
Additionally, CMS anhedonic-like rats display depression-associated cognitive impairments, indicated by lower 
performance in a translational touchscreen learning task, which was not found in CMS resilient, hedonic  rats11. 
Hence, cognitive impairments are specific to the depression-like phenotype. In the present study, we follow up 
by assessing the efficacy of a relatively novel, multimodal antidepressant on affective symptoms and cognitive 
deficits in the CMS model.
Vortioxetine was approved as an antidepressant in  201312. In addition to an antidepressant action, a pro-cogni-
tive effect was ascribed to vortioxetine due to its multimodal mechanism of  action13. In MDD patients, executive 
functions, attention, speed of processing, verbal learning and memory functions, as well as affective symptoms, 
have been shown to recover after chronic vortioxetine  intervention14. In rodents, vortioxetine improved spatial 
working memory, visuo-spatial memory and contextual fear memory besides increasing synaptic plasticity and 
decreasing behavioural  despair15–19. Although the CMS model shows high predictive validity for antidepressant 
 actions20,21, unexpectedly, vortioxetine was reported to be ineffective in the CMS  model22. Thus, we investigated, 
in the present study, if vortioxetine can alleviate the anhedonic-like phenotype of CMS exposed rats using a 
different route of drug administration. Moreover, cognition of these rats was assessed in the different paired-
associates learning (dPAL) touchscreen task, a standardized tool in clinical as well as in preclinical  research23,24. 
The rather novel rodent touchscreen platform involves appetitive operant conditioning and was developed based 
on the human Cambridge Neuropsychological Test Automated Battery (CANTAB); the most frequently applied 
cognitive assessment tool in depression  research4. Finally, hippocampal (HPC) and prefrontal cortex (PFC) 
gene expression was analysed to link neurobehavioral alterations with underlying molecular changes. Genes 
that are thought to play a role in psychiatric disorders and/or the stress response, such as the mineralocorticoid 
receptor (Nr3c2), glucocorticoid receptor (Nr3c1), FK506 binding protein 5 (Fkbp5), glycogen synthase kinase 
3 beta (Gsk3b), disrupted in Schizophrenia 1 (Disc1) and brain-derived neurotrophic factor (Bdnf) as well as 
genes important in cognition and neuronal plasticity, such as neuroregulin 1 (Nrg1), homer scaffolding protein 
1–3 (Homer1–3), Shank 1–3, Spinophilin and Cofilin 1, were analysed.
In short, this study aimed to investigate the effect of vortioxetine on the affective state, cognitive performance 
and cerebral gene expression.
Materials and methods
Animals. Male Long-Evans (LE) rats (Janvier Labs, France; n = 242) were 5–6 weeks of age weighing 100–
120 g at arrival. Rats were single-housed during the experiment with free access to food and water (unless oth-
erwise stated) and kept on a 12-h light–dark cycle. All experiments were conducted according to EU Directive 
2010/63/EU, in compliance with the ARRIVE guidelines and approved by the Danish National Committee for 
Ethics in Animal Experimentation (2013-15-2934-00814).
Chronic mild stress paradigm. A 1-h sucrose consumption test (SCT, 1.5%) was carried out weekly to 
assess the hedonic state of each rat throughout the experiment (Supplementary Methods). Following three base-
line SCTs, rats were exposed to a number of variable, unpredictable mild stressors in a two-week repeated pro-
tocol (Table S1) to provoke a depressive-like phenotype.
After five weeks of CMS, stress exposed rats with a SCT index ≤ 0.7 (average of SCTs in week 4–5 normalised 
to baseline) were categorized anhedonic-like according to an a priori  cutoff25,26 and remained in the study.
Following nine weeks of CMS, which included an initial four weeks of drug treatment, a modified CMS 
protocol was used (Fig. 1A). Stressors were only applied during the nights reserving daytime for touchscreen 
assessment. Every Friday, the SCT was carried out followed by 4 h of grouping and light stressors. Thus, touch-
screen testing was discontinued on Fridays. The modified CMS schedule (Table S2) was changed every second 
week to prevent habituation to the milder stress protocol.
Drug administration. After five weeks of CMS, 45 and 12 anhedonic-like animals were randomly assigned 
to treatment with vortioxetine or vehicle (Fig. 1A). Group means and standard deviations of the last SCT index 
before treatment start were comparable for treatment and vehicle group. Standard rat chow (Altromin 1324, Bro-
gaarden, Denmark) was supplemented with vortioxetine (Carbosynth Ltd., UK) at a concentration of 1.8 g/kg rat 
chow in order to reach a therapeutic dose range with a SERT occupancy above 90%27. Following four weeks of 
treatment combined with CMS, rats were subdivided into high responders (10 rats with highest recovery accord-
ing to SCT index) and low responders (10 rats with lowest recovery according to SCT index) and subjected to 
touchscreen testing.
Touchscreen operant platform. Food reduction and touchscreen pre‑training. After nine weeks of CMS 
and four weeks of treatment, 40 rats (control, anhedonic-like, responder, low-responder; n = 10/group) were 
used for touchscreen testing. First, rats were gradually food restricted to 75% of their individual ad  libitum 
consumption (Table S3)11. Body weights were monitored daily to ensure rats maintain at least 90% of their body 
weight during food restriction. Additionally, rats were introduced to peanut butter (Bilka, Denmark) and bacon 
pellets (45 mg dustless precision pellets, Bio Serv, Flemington, NJ, USA) used for operant conditioning during 
touchscreen testing. Pre-training was conducted after eight days of food restriction. In four steps, rats were 
conditioned to operate the touchscreen chamber (Fig. 1B). For further details on pre-training and the Bussey-
Saksida touchscreen operant chambers (Campden Instruments Ltd., Loughborough, UK) see Supplementary 
Method section. Experimenters carrying out behavioural testing were blinded to group identity.
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Paired‑associates learning touchscreen task. Cognitive performance was assessed in the dPAL task, in which 
a specific symbol-location association needs to be learned. In each trial, only two of the three symbols (spider, 
flower, plane) would be displayed, one in its correct location (S +) and the other symbol in an incorrect location 
(S-) on the touchscreen. The third window was left blank (Supplementary Fig. S1). A touch to S + resulted in 
reward pellet delivery followed by a 20 s inter-trial interval (ITI). Poking S- was followed by a 5 s time out with 
house light on, the ITI and a correction trial (repetition of the incorrect trial until correct). The six trial types 
resulting from the stimulus-location association pairs were balanced over the course of a session. dPAL criterion 
was achieved by completing 75 trials (excluding correction trials) with at least 60 correct trials (≥ 80% accuracy) 
within 45 min on two consecutive days. Rats that did not acquire the task within 46 session were marked as fail-
ing the task by an a priori criterion from a previous  study11.
Retention of the dPAL task. Passing the dPAL task was ensued by a 10-day hiatus without touchscreen testing 
and an increase in food availability. Rats were then re-tested on the dPAL task for two days to assess long-term 
memory.
Cerebral gene expression. A circadian rhythm of BDNF has been reported in certain brain  regions28,29. 
Therefore, the rats were sacrificed under similar standardized time conditions from 2 to 4  pm, 1–3  days 
(Mean = 1.3 days) after completing the dPAL retention testing. To diminish a possible effect of the testing, the 
rats were distributed across the four groups at day 1 to 3. The brain was removed and PFC, dorsal and ven-
tral HPC were dissected and snap frozen on dry-ice. RNA was extracted using the PARIS RNA isolation kit 
(Ambion, TX, USA). The samples were processed as previously  described30 and real-time qPCR was performed. 
A detailed description of RNA extraction and qPCR can be found in Supplementary Methods.
Statistical analysis. SCT data were analysed by a two-way ANOVA (time x group), followed by group-wise 
post-hoc comparisons. SCT data are displayed and included in the analysis until the time point when the first 
animal was terminated after completing the dPAL task.
Summary statistics of the dPAL task (see results section ‘Acquisition of the dPAL task’) were analysed by 
applying two-way ANOVA (hedonic state x treatment) or by rank aligned two-way ANOVA (indicated with 
Frank) if assumptions of normality (assessed with QQ-plots) or homogeneity of variance (assessed with Bartlett’s 
test) were violated. Furthermore, one outlier in the control group for median response latency and two outliers 
Figure 1.  Experimental design. (A) Study design. Sucrose consumption tests (SCTs) were conducted 
throughout the experiment to measure baseline sucrose intake, stress and drug effects (discriminating high 
vs low respond to treatment). Touchscreen testing included food reduction, pre-training, different paired-
associates learning (dPAL) task acquisition and retention. Rats were euthanized and brain tissue was collected 
(X) 1–3 days after dPAL retention test. (B) Touchscreen pre-training. Passing criteria to move on to the next 
stage are indicated alongside the arrows. Peanut butter was added to the screen when the rat entered “must 
touch” or when performing ≤ 40 touches in the previous “must touch” session.
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(control and low-responder) for number redundant screen touches were determined by Grubbs (α = 0.05) or 
ROUT (Q = 1%) test (Prism 7, GraphPad Software Inc., CA, USA) and excluded.
Repeated measurement data analysing learning behaviour across the task (results section ‘Learning phase of 
the dPAL task’) and learning behaviour within a session (‘Learning behaviour within a single dPAL session’ & 
Supplementary Results) included all animals (acquiring and failing dPAL acquisition), whereas retention data 
(‘Long-term memory of dPAL task’ & Supplementary Results) only included animals passing the dPAL task. 
The data were analysed with repeated measures ANOVA of type III if significant interaction effect was present, 
otherwise with type II. Mauchly’s sphericity test, if significant, led to Greenhouse–Geisser (GG) (ε < 0.75) or 
Huynh–Feldt (HF)-corrected repeated measures ANOVA (indicated with FGG or FHF). Post-hoc comparisons were 
Bonferroni-corrected. In a separate analysis of memory and relearning performance (Supplementary Results), 
data were analysed by two-way ANOVA as described in summary statistics.
Normalised target genes were displayed as percent of control group mean (PFC data) or percent of dorsal 
HPC control mean (dorsal and ventral HPC data) and analysed by two-way ANOVA as described in summary 
statistics. Differences between dorsal and ventral HPC gene expression were analysed with Student’s t-test. Sup-
plementary Table S5 displays n-number for each gene and group, thus, the number of outliers removed.
Statistical significance was accepted at p < 0.05, two-tailed. Effect size is reported as eta squared (η2; summary 
statistics) or generalised eta squared (η2G; repeated measures) for cognitive  results31. All post-hoc comparisons 
were Bonferroni-corrected. Statistical analyses were performed with RStudio (Version 0.99.892, Boston, USA) 
and data were displayed with GraphPad Prism 7.
Results
Hedonic‑like status in response to CMS and vortioxetine treatment. Following a significant 
interaction effect of group x time (F(45,540) = 5.52, p < 0.0001; two-way ANOVA) and main effects of time 
(F(15,540) = 12.82, p < 0.0001) and group (F(3,36) = 32.24, p < 0.0001), Bonferroni-corrected post-hoc analysis 
revealed that anhedonic-like rats consumed significantly less sucrose during all SCTs compared to non-stressed 
control rats (p < 0.0001). Sixty-five percent of treated rats responded well to vortioxetine and their sucrose intake 
was not statistically significant different from non-stressed controls, but significantly increased compared to 
untreated, anhedonic-like rats (p < 0.0001). Rats that responded poorly to vortioxetine, thus low-responders, 
consumed significantly less sucrose than responders (p < 0.0001) or non-stressed controls (p < 0.0001), but were 
not statistically significantly different to anhedonic-like rats (Fig. 2).
Paired‑associates learning touchscreen task. Acquisition of the dPAL task. Acquisition of the dPAL 
task, indicated by the accumulated number of trials over all sessions to reach criterion for passing, did not differ 
significantly between groups (Fig. 3A).
Two-way ANOVA revealed that drug treatment increased the number of redundant screen touches com-
pared to untreated animals (main effect of treatment: F(1,28) = 9.98, p = 0.004, η2 = 0.23). This treatment effect 
is possibly driven by a trend in hedonic state x treatment interaction effect (F(1,28) = 1.12, p = 0.063, η2 = 0.08), 
i.e. responders diverging (Fig. 3B).
Figure 2.  Sucrose consumption test. The consumption index displays the sucrose consumption normalised to 
baseline sucrose intake prior to CMS exposure. (A) Start of antidepressant treatment with vortioxetine. (B) Food 
restriction for touchscreen testing initiated. (C) Touchscreen pre-training followed by dPAL acquisition. Group 
means (± SEM) are displayed. Bonferroni-corrected group comparisons over the entire study are indicated with 
****p < 0.0001 (n = 10 for all groups).
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Median response latency was altered due to a hedonic state x treatment interaction effect (F(1,29) = 9.03, 
p = 0.005, η2 = 0.15; Fig. 3C). Specifically, anhedonic-like rats (p = 0.013), responders (p = 0.0001) and low-
responders (p = 0.001) responded faster to touchscreen stimuli than non-stressed control rats. Furthermore, 
treatment alone reduced median response latency (F(1,29) = 17.58, p = 0.0002, η2 = 0.30; Fig. 3C).
There was no difference in reward collection latency (Fig. 3D) or number of correction trials between groups.
Six animals (one non-stressed control, three anhedonic-like rats, one responder and one low-responder) did 
not pass dPAL and, thus, were excluded from this analysis.
Learning phase of the dPAL task. To compare learning curves with repeated measures ANOVA, the rats’ vari-
able number of sessions and trials per session was  normalised32. Thus, for each rat, the total number of trials 
(trials + correction trials) to learn the dPAL task was split into ten equal  bins11.
The percentage of correct trials (accuracy) increased significantly over time, thus, with increasing number 
of bins (FGG(3.00,107.98) = 30.08, p < 0.0001, η2G = 0.08), indicating task learning. No effect of group on accuracy 
was observed (Fig. 4A).
The number of trials performed increased significantly over time with growing bin number 
(FGG(3.08,110.85) = 47.90, p < 0.0001, η2G = 0.10), whereas the number of correction trials decreased significantly 
by bin number (FGG(3.08,110.73) = 48.37, p < 0.0001, η2G = 0.17; Fig. 4B). This also indicates learning of the task, 
however, no statistically significant differences between groups were observed.
Control rats responded slower to stimuli compared to anhedonic-like rats (p = 0.002), low-responders 
(p < 0.0001) or responders (p < 0.0001). However, vortioxetine responders showed the shortest median response 
latency compared to controls, anhedonic-like rats (p = 0.002) and low-responders (p = 0.029; main effect of group: 
F(3,36) = 3.24, p = 0.033, η2G = 0.15). The median response latency decreased significantly during dPAL acquisition 
(main effect of time: FGG(4.32,155.40) = 9.14, p < 0.0001, η2G = 0.08; Fig. 4C).
Vortioxetine responders executed the highest number of redundant screen touches per trial compared to 
control rats (p < 0.0001) and anhedonic-like rats (p < 0.0001). Vortioxetine low-responders also performed more 
redundant screen touches than control (p = 0.022) and anhedonic-like rats (p = 0.005; main effect of group: 
F(3,36) = 3.10, p = 0.039, η2G = 0.13). The number of redundant screen touches decreased during dPAL acquisition 
(main effect of time: FGG(2.46,88.45) = 5.67, p < 0.0001, η2G = 0.06; Fig. 4D).
Collection latency was not significantly different between groups or over time, suggesting equal motivation 
for reward collection and for engaging in the dPAL task.
Figure 3.  Acquisition of dPAL task. (A) The accumulated number of trials needed to acquire the dPAL task. 
(B) The number of additional, i.e. redundant screen touches per trial (trial or correction trial) averaged across 
all sessions for each animal. (C) Median response latency to touchscreen stimuli averaged across all sessions. 
(D) Reward collection latency averaged across all sessions. Only animals, which acquire the dPAL task, are 
analysed and displayed as individual data points and group means (± SEM). Two-way ANOVA main effects and 
Bonferroni post-hoc comparisons are indicated by *p < 0.05, **p < 0.01, ***p < 0.001.
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Learning behaviour within a single dPAL session. Every single session of an animal was divided into six blocks 
by reference to the total number of trials (trials + correction trials). Average performance per block was deter-
mined for each animal. This allowed analysis of learning behaviour within the time course of a session.
During a session, accuracy did not change significantly over time, nor between groups. The number of trials 
executed during a session changed depending on session block (main effect of session block: F(5,180) = 3.38, 
p = 0.006, η2G = 0.02; Supplementary Fig. S2A). For further details see Supplementary Result Section.
Long‑term memory of dPAL task. Long-term memory performance was assessed by re-testing rats in dPAL 
following a 10-day hiatus after dPAL acquisition. Included in the analysis was accuracy of the last session of 
dPAL acquisition before the break as well as the two dPAL retention sessions after the break. A trend of an 
interaction effect of group x session (FGG(4.28,42.75) = 2.10, p = 0.066, η2G = 0.05) and a main effect of time 
(FGG(1.43,42.75) = 8.91, p = 0.0004, η2G = 0.36) on accuracy was observed. Bonferroni post-hoc comparisons 
revealed that all groups decreased accuracy of task retention in session one, vortioxetine responders signifi-
cantly increased their accuracy on retention session two and all groups continued to show a lower accuracy on 
session two compared to passing criterion (Supplementary Fig.  S3A). For further details see Supplementary 
Result Section.
Cerebral gene expression. Alterations in gene expression levels were analysed in response to vortioxetine 
treatment and hedonic state. Furthermore, differences between dorsal and ventral HPC gene expression were 
examined. Regulated genes are presented in Fig. 5. Supplementary Table S5 contains all gene expression levels 
for the four groups and all tissues.
Prefrontal cortex gene expression. In the PFC, the expression level of Cofilin 1 was increased in the anhedonic-
like group (p = 0.022) compared to controls (interaction effect of hedonic state x treatment: Frank(1,28) = 5.51, 
p = 0.026). A trend of treatment reducing expression of Nr3c1 mRNA was observed (F(1,27) = 4.07, p = 0.054). 
The mRNA expression levels of Nr3c2, Fkbp5, Disc1, Gsk3b, Bdnf, Shank 1–3, Homer1–3, Nrg1, and Spinophilin 
were not affected.
Figure 4.  Behavioural parameters during dPAL task acquisition of all animals. (A) Accuracy; percent of correct 
choices. (B) Number of trials (black) and number of total trials (trials plus correction trials, grey). (C) Median 
response latency. (D) Number of additional, i.e. redundant screen touches per trial (trial or correction trial). 
Group means (± SEM) are shown with ‘ + ’ indicating a significant difference of the respective group to the three 
other groups and ‘ ~ ’ indicating a significant difference to controls and anhedonic-like rats (Bonferroni post-hoc 
comparisons; n = 10 for all groups).
7
Vol.:(0123456789)
Scientific Reports |         (2021) 11:9113  | https://doi.org/10.1038/s41598-021-88462-7
www.nature.com/scientificreports/
Hippocampal gene expression. The gene expression of Gsk3b, Disc1, Shank1, Shank2, and Nrg1 was higher in the 
ventral compared to dorsal HPC (t(35) =  − 3.13, p = 0.004; t(34) =  − 4.72, p < 0.0001; t(34) =  − 3.99, p = 0.0003; 
t(32) = − 3.58, p = 0.001; and t(32) = − 5.84, p < 0.0001, respectively). For Homer1 the expression was decreased in 
the ventral compared to the dorsal HPC (t(35) = 3.01, p = 0.005).
In the dorsal HPC, Homer2 gene expression was decreased in groups with anhedonic-like phenotype (main 
effect of hedonic state: F(1,33) = 5.63, p = 0.024; Fig. 5).
Close to significant trends due to treatment and/or hedonic state were observed for Nr3c2, Disc1, Gsk3b, Bdnf 
and Homer3 mRNA levels (Fig. 5; statistics in Table S5); with no notable observations on Fkbp5, Nr3c1, Shank3, 
Spinophilin, or Cofilin 1 gene expression across tissues, hedonic state or treatment.
Discussion
In the present CMS study, non-stressed controls, anhedonic-like rats and vortioxetine treated rats were assessed 
for hedonic state, cognitive performance and cerebral gene expression profiling.
Vortioxetine recovers the hedonic state. CMS exposed rats decreased sucrose intake over time, indi-
cating a reduced reward sensitivity and, hence, mirroring the MDD core symptom anhedonia. Administration 
of the antidepressant vortioxetine recovered the hedonic state in a major fraction of anhedonic-like rats (65%), 
whereas the remaining rats responded poorly and remained in an anhedonic-like state. Previously vortioxetine 
was reported to be ineffective when tested in the CMS  model22. However, vortioxetine was administered by 
intraperitoneal injections once daily (Mariusz Papp, personal communication), and the relatively short half-
life of vortioxetine in  rodents22 may explain for the ineffective treatment outcomes in this study. In the present 
study vortioxetine was mixed into the diet and, hence, this route of drug administration ensured a more even 
and continuous diurnal drug exposure. In a parallel study using the same dose and route of administration, we 
Figure 5.  Prefrontal cortex (PFC) and hippocampal (HPC) gene expression levels. Genes of interest are 
normalised to reference genes and displayed as percent of control mean for the PFC or as percent of the control 
mean of the dorsal HPC for ventral and dorsal HPC tissue. Individual data points as well as group means 
(± SEM) are displayed. Statistical significance is indicated for main effects and between tissue differences 
(angular brackets), and Bonferroni corrected post-hoc comparisons by ****p < 0.0001, ***p < 0.001, **p < 0.01, 
*p < 0.05; and trends by the respective number. Bdnf—Brain-derived neurotrophic factor; Disc1—Disrupted 
in Schizophrenia 1; Gsk3b—Glycogen synthase kinase 3 beta; Homer—Homer scaffolding protein; Nr3c1—
Glucocorticoid receptor; Nr3c2—Mineralocorticoid receptor; Nrg1—Neuroregulin 1.
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confirmed comparable vortioxetine serum levels (unpublished data) as shown to be therapeutically  relevant27,33. 
Food restriction necessary for touchscreen training likely resulted in a slightly reduced dose of vortioxetine. 
However, this reduction was comparable across animals and groups (Suplementary Fig.  S5). Furthermore, 
monitoring of the hedonic state with SCTs throughout the study (Fig. 2) showed that vortioxetine responders 
remained comparable to controls and above the criterion for anhedonia even during food reduction.
Vortioxetine affects cognition. In the present study we also investigated whether vortioxetine-induced 
alleviation of the hedonic state is associated with alterations in cognitive performance. Vortioxetine has been 
reported to augment cognitive  functions22 and is believed to be a directly mediated effect rather than caused 
through remission from affective  symptoms14. In the present study, vortioxetine did not alter primary touch-
screen parameters (accuracy, number of trials) compared to non-stressed controls or anhedonic-like rats. How-
ever, we noticed that three out of ten anhedonic-like rats did not pass the dPAL task within 46 sessions whereas 
only one animal failed to pass in any of the other groups. This observation might be attributed to normal biologi-
cal variation considering the small group size (n = 10). Alternatively, the inability to acquire the dPAL task might 
suggest cognitive impairment in the anhedonic-like group and, consequently, a potential pro-cognitive effect of 
vortioxetine treatment. Future studies are needed to validate this interpretation.
Importantly, the latency for collecting reward pellets did not differ between groups. This suggests equal 
incentive to consume the reward and presumably to participate in the touchscreen task. Likely, this behaviour 
is driven by hunger due to the food restriction accompanying touchscreen  testing11.
Consistently, median response latency was reduced in all CMS-exposed groups compared to controls. Dur-
ing task acquisition, vortioxetine responders displayed the shortest median response latency and controls the 
longest latency. Prolonged median response latency in the control group is consistent with a previous  study25, 
suggesting increased cognitive appraisal, before executing a choice in control animals. Consequently, reduced 
response latency in the anhedonic and mainly in the vortioxetine treated groups can be considered as impulsive 
behaviour, executing a less evaluated, spontaneous choice. Reduced response latency may indicate impaired 
HPC functioning since inactivation of the dorsal HPC with lidocaine and scopolamine significantly shortened 
reaction time in the rat dPAL task as  well34 and is in line with the important role of HPC in visuospatial learning 
 tasks32,35. An alternative explanation might include a frontostriatal reorganization causing a shift from effortful, 
goal-directed to habitual behaviour. Such changes have been observed after stress  exposure36 and might explain 
the reduced response latency observed in the present study. Noticeably, responders to vortioxetine treatment 
displayed the shortest response latency of all groups suggesting an association between treatment response and 
decreased appraisal.
A shift to habit-like or impulsive behaviour is further supported by the number of redundant screen touches 
per trial. Consistently, vortioxetine treated rats executed more redundant touches than any other group. Thus, 
vortioxetine seems to increase impulsive or compulsive behaviour. This lack of inhibitory control may suggest 
impairments in executive function associated with the  PFC37.
In order to address long-term memory, accuracy was re-tested after a 10-day hiatus subsequent to passing 
dPAL. Vortioxetine responders decreased most in accuracy after the 10-day hiatus and performed significantly 
worse than low-responders. Hence, a high response to vortioxetine treatment was associated with reduced 
memory performance. Interestingly, only the control group restored performance to the dPAL passing criterion 
level (≥ 80% accuracy) on the second day of retention. All other groups still performed below 80% accuracy and 
the anhedonic-like group even decreased in accuracy on the second day of retention.
Altered cerebral gene expression associated with vortioxetine treatment and hedonic 
state. Expression levels of genes regulated in neuropsychiatric diseases or associated with neuronal plasticity 
were measured in the PFC, dorsal and ventral HPC. Cofilin 1 is a key regulator in growth cone dynamics and, 
thus, in neuronal plasticity important for learning and  memory38,39. In the PFC, Cofilin 1 expression was upregu-
lated in anhedonic-like rats compared to controls. Excessive up- or down-regulation of Cofilin 1 was associated 
with impaired synaptic plasticity and learning  deficits39. Thus, altered Cofilin 1 gene expression might suggest 
subthreshold cognitive impairments associated with anhedonia, especially in untreated rats.
DISC1 is a scaffolding protein involved in neurodevelopmental signalling and suggested as candidate gene 
in neuropsychiatric  disorder40,41. In the present study, Disc1 gene expression levels were higher in the ventral 
compared to the dorsal HPC. In the ventral HPC, an interaction trend may indicate a regulatory association of 
the hedonic state and vortioxetine treatment on Disc1 gene expression. These changes support the literature that 
DISC1 dysregulation is involved in the pathology of mental illnesses including cognitive deficits and dendritic 
 arborisation42,43.
DISC1 regulates downstream Gsk3b expression and in the present study, Gsk3b expression was upregulated 
in the ventral compared to the dorsal HPC, which might be linked to an increased Disc1 gene expression. Gsk3b 
expression is known to be inhibited by most antidepressant treatments, e.g. SSRIs, and a dysregulation of Gsk3b 
expression is suggested to be implicated in  depression44–47. Gsk3b upregulation is associated with impairments 
in spatial memory, attention and long-term potentiation, which are all important elements in acquisition of the 
dPAL  task48–52. Consequently, borderline increased Gsk3b gene expression levels in the dorsal HPC in the present 
study may underlie the observed memory impairments during dPAL retention in the vortioxetine responder 
group compared to low-responders.
Homer proteins, which are scaffolding proteins facilitating post-synaptic signalling, are vital for learning and 
memory  functions53. Moreover, decreased Homer1 expression is associated with an enhanced stress response 
and susceptibility to psychiatric diseases such as  MDD54,55. In the present study, Homer1 was higher expressed 
in the dorsal than in the ventral HPC, possibly in response to spatial learning required for dPAL  acquisition56. 
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In the dorsal HPC, Homer2 mRNA expression was decreased in rats with anhedonic phenotype (treated and 
untreated). Homer2 is required for alcohol-seeking57 and, thus, reduced seeking of reward in anhedonic-like rats 
may be reflected by decreased Homer2 levels. Although Homer3 was upregulated in rat frontal cortex in response 
to vortioxetine treatment (not correcting of multiple comparisons)58, only a trend of vortioxetine downregulating 
Homer3 expression in the ventral hippocampus was observed in the present study.
Bdnf is involved in neuronal  plasticity59, a mechanism which might be upregulated by vortioxetine  treatment58. 
Moreover, Bdnf expression levels are reduced following stress exposure as well as in PFC and HPC post‑mortem 
tissue of MDD suicide  victims60,61. Furthermore, antidepressant treatment elevates Bdnf levels and, in turn, treat-
ment efficacy appears dependent on Bdnf  levels62–64. Consequently, the trend of higher Bdnf levels in the dorsal 
HPC of vortioxetine treated animals is in accordance with the literature.
NR3C2 expression is an important player in the stress response, HPA axis activity and MDD. Increased 
NR3C2 function is associated with resilience, whereas decreased NR3C2 levels suggest stress-susceptibility for 
developing  depression65. Hence, the anhedonic phenotype, i.e. susceptibility to CMS including a low treatment 
response to vortioxetine, might be linked to a reduced Nr3c2 expression in the HPC.
In future studies, it would be interesting to include gene expression profiling before start of behavioural testing 
as well as after or, alternatively, a behaviourally naïve, vortioxetine-treated group can be added to disentangle the 
effects of the learning paradigm from treatment effects.
Touchscreen testing. To our knowledge, this was the first touchscreen study to show that not only sweet 
rewards, such as sugar pellets or milkshakes, generate successful operant conditioning. This might become cru-
cial in addiction, diabetes or reward studies and expands the applicability of touchscreen testing. Furthermore, 
continuous SCTs throughout the experiment revealed the impact of food reduction, treatment and appetitive 
touchscreen testing on rodents.
Conclusion
Our study expands on the relatively new drug treatment approach of antidepressants targeting depression-
associated cognitive impairments. Hence, the effect of vortioxetine on the hedonic state, on cognition and 
selected gene expression was assessed. In contrast to a previous report (reviewed in Sanchez et al.22), we have 
shown that vortioxetine recovers the hedonic state in anhedonic-like rats and, hence, demonstrated its efficacy 
in a well-validated preclinical model of  depression26,66,67. Moreover, cognitive performance was assessed with the 
touchscreen operant platform, which was developed with focus on its translational value. In the present study, the 
primary readouts did not reveal beneficial cognitive effects of vortioxetine treatment although it was observed 
that a higher number of treated rats managed to pass the dPAL task. Furthermore, effects on behavioural strategy 
was evident from secondary read-outs. The potential pro-cognitive effect of vortioxetine requires more detailed 
evaluation since the observed effects, such as shortened reaction time and a shift to habitual behaviour might be 
beneficial in a different context than what the dPAL touchscreen task is actually designed for addressing. Finally, 
the most pronounced alterations in the selected genes were in the dorsal versus the ventral HPC. However, it 
cannot be excluded that the learning paradigm has affected the gene expression profiles.
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